Abstract
In the last two decades, bisphosphonates and denosumab have been instrumental in the treatment of patients suffering with prostatic cancer bone metastases [17]. Recently abiraterone and enzalutamide have demonstrated potential beneficial effects on bone metabolism delaying and reducing skeletal complications. Even with recent improvements in medical treatment of skeletal metastases in prostate cancer, the development of effective and precise therapies aimed to improve patients’ prognosis and quality of life remains a clinical challenge.
Cite
CITATION STYLE
Santini, D., Ripamonti, C., Zoccoli, A., Iuliani, M., Fioramonti, M., Ribelli, G., & Pantano, F. (2016). Bone-targeted agents. In Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management (pp. 181–192). Springer International Publishing. https://doi.org/10.1007/978-3-319-42327-2_15
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
